AGRX(Delisted)
Agile Therapeutics·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AGRX
Agile Therapeutics,Inc.
A forward-thinking women's healthcare company that develops prescription contraceptive products
500 College Road East, Suite 310, Princeton, New Jersey 08540
--
Agile Therapeutics, Inc., was incorporated in Delaware on December 22, 1997. The company is a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products. Agile's product candidates are designed to provide women with more convenient and compliant contraceptive options. Agile has developed a patented technology for transdermal patches called Skinfusion, which aims to provide better adhesion, stability and patient acceptance than currently available drug patches. The company's lead product candidate, Twirla, also known as AG200-15, is a once-a-week prescription contraceptive patch that is currently in Phase 3 clinical development. Currently, only one additional contraceptive patch is available in the United States, and the patch is limited due to its dosage and physical properties. And Twirla is designed to address these limitations.
Company Financials
EPS
AGRX has released its 2023 Q3 earnings. EPS was reported at -1.47, versus the expected -1.84, beating expectations. The chart below visualizes how AGRX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
AGRX has released its 2023 Q3 earnings report, with revenue of 6.66M, reflecting a YoY change of 121.92%, and net profit of -799.00K, showing a YoY change of 86.53%. The Sankey diagram below clearly presents AGRX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
